(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
04 September 2025 (04.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/184301 A1

(51) International Patent Classification:
C12N 15/113 (2010.01) *A61K 31/713* (2006.01)
A61K 31/711 (2006.01) *A61P 1/16* (2006.01)
A61K 31/7115 (2006.01) *A61P 3/06* (2006.01)
A61K 31/7125 (2006.01)

(21) International Application Number:
PCT/US2025/017533

(22) International Filing Date:
27 February 2025 (27.02.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/559,682 29 February 2024 (29.02.2024) US
63/685,514 21 August 2024 (21.08.2024) US

(71) Applicant: **ARROWHEAD PHARMACEUTICALS, INC.** [US/US]; 177 East Colorado Boulevard, Suite 700, Pasadena, California 91105 (US).

(72) Inventors: **VAN DYKE, Jonathan**; Arrowhead Pharmaceuticals, Inc., 502 S. Rosa Road, MADISON, Wisconsin 53719 (US). **KLOSSOWSKI, Szymon**; Arrowhead Pharmaceuticals, Inc., 502 S. Rosa Road, MADISON, Wisconsin 53719 (US). **GLEBOCKA, Agnieszka**; Arrowhead Pharmaceuticals, Inc., 502 S. Rosa Road, MADISON, Wisconsin 53719 (US). **DING, Zhi-Ming**; Arrowhead Pharmaceuticals, Inc., 502 S. Rosa Road, MADISON, Wisconsin 53719 (US). **PEI, Tao**; Arrowhead Pharmaceuticals, Inc., 502 S. Rosa Road, MADISON, Wisconsin 53719 (US).

(74) Agent: **CHEN, Meibo**; Arrowhead Pharmaceuticals, Inc., 502 S. Rosa Road, MADISON, Wisconsin 53719 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2025/184301 A1

(54) Title: RNAI AGENTS FOR DUAL INHIBITION OF EXPRESSION OF APOLIPOPROTEIN C-III (APOC3) AND PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9), COMPOSITIONS THEREOF, AND METHODS OF USE

(57) Abstract: Described are RNAi agents, compositions that include RNAi agents, and methods for dual inhibition of an Apolipoprotein C-III (APOC3) and Proprotein Convertase Subtilisin Kexin 9 (PCSK9) gene. The APOC3-PCSK9 RNAi agents disclosed herein inhibit the expression of an APOC3 and a PCSK9 gene. Pharmaceutical compositions that include one or more APOC3-PCSK9 RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described TSLP RNAi agents to hepatic cells, in vivo, provides for inhibition of APOC3 and/or PCSK9 gene expression, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including hypertriglyceridemia and hypercholesterolemia.